GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SQI Diagnostics Inc (OTCPK:SQIDF) » Definitions » COGS-to-Revenue

SQI Diagnostics (SQI Diagnostics) COGS-to-Revenue : 0.48 (As of Mar. 2023)


View and export this data going back to 2009. Start your Free Trial

What is SQI Diagnostics COGS-to-Revenue?

SQI Diagnostics's Cost of Goods Sold for the three months ended in Mar. 2023 was $0.09 Mil. Its Revenue for the three months ended in Mar. 2023 was $0.19 Mil.

SQI Diagnostics's COGS to Revenue for the three months ended in Mar. 2023 was 0.48.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. SQI Diagnostics's Gross Margin % for the three months ended in Mar. 2023 was 51.61%.


SQI Diagnostics COGS-to-Revenue Historical Data

The historical data trend for SQI Diagnostics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SQI Diagnostics COGS-to-Revenue Chart

SQI Diagnostics Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.66 0.32 0.23 0.16 0.62

SQI Diagnostics Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 0.64 1.28 0.73 0.48

SQI Diagnostics COGS-to-Revenue Calculation

SQI Diagnostics's COGS to Revenue for the fiscal year that ended in Sep. 2022 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=3.748 / 6.074
=0.62

SQI Diagnostics's COGS to Revenue for the quarter that ended in Mar. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.09 / 0.186
=0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SQI Diagnostics  (OTCPK:SQIDF) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

SQI Diagnostics's Gross Margin % for the three months ended in Mar. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0.09 / 0.186
=51.61 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


SQI Diagnostics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of SQI Diagnostics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


SQI Diagnostics (SQI Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
36 Meteor Drive, Toronto, ON, CAN, M9W 1A4
SQI Diagnostics Inc is the leader in the field of lung health. The company develops and manufactures respiratory health and precision medicine tests that run on SQI's automated systems. The company is developing tests to simplify and improve COVID-19 antibody monitoring, rapid acute lung injury testing, donor organ transplant informatics, and immunological protein and antibody testing. Its geographical segments are the United States, Canada, and Europe. Canada accounts for more than half of its revenues.

SQI Diagnostics (SQI Diagnostics) Headlines